预测并验证COVID-19大流行对慢性肾脏病患者影响的回顾性队列研究
CKD患者合并症负担重,合并症与SARS-CoV-2感染相关(透析/移植OR 2.08,95%CI 2.04-2.13;心力衰竭OR 1.73,95%CI 1.71-1.76;癌症OR 1.01,95%CI 1.01-1.04)。观察超额死亡34265例,预测死亡28746和24546例(感染率10%,相对风险3.0)及23754和20283例(观察感染率6.7%,相对风险3.7)。
要点
- CKD患者合并症常见:患病CKD中73.5%有≥1种合并症、13.2%有≥3种;新发CKD中71.2%有≥1种、11.2%有≥3种。
- 透析/移植(OR 2.08,95%CI 2.04-2.13)和心力衰竭(OR 1.73,95%CI 1.71-1.76)与SARS-CoV-2感染相关,癌症(OR 1.01,95%CI 1.01-1.04)与之无关。
- 观察超额死亡34265例,预测死亡分别为28746和24546例(感染率10%,相对风险3.0)及23754和20283例(观察感染率6.7%,相对风险3.7)。
核心结论
- CKD患者合并症和多病共存负担高,大流行前和大流行期间死亡风险均高。
- 治疗合并症、非药物措施和疫苗接种是CKD患者的优先事项,大流行期间及之后长期疾病管理均重要。
研究设计与样本
- 分析患病CKD(1,934,585例)和新发CKD(144,969例)患者的合并症患病率、SARS-CoV-2感染和死亡。
- 控制年龄、性别和疫苗接种后评估基线死亡风险、感染发生率及合并症结局。
- 使用已发表模型在大流行前CKD队列(NHSD TRE和CPRD)中比较不同人群感染率和疫情相关相对风险下观察与预测的一年死亡率。
主要发现
- 患病CKD中73.5%有≥1种合并症、13.2%有≥3种;新发CKD中71.2%有≥1种、11.2%有≥3种。
- 透析/移植与SARS-CoV-2感染相关(OR 2.08,95%CI 2.04-2.13),心力衰竭相关(OR 1.73,95%CI 1.71-1.76),癌症无关(OR 1.01,95%CI 1.01-1.04)。
- 一年全因死亡率随年龄、性别、多病共存和CKD分期变化。
- 观察超额死亡34265例;NHSD-TRE和CPRD数据库分别预测28746和24546例死亡(感染率10%,相对风险3.0),以及23754和20283例死亡(观察感染率6.7%,相对风险3.7)。
临床怎么用
- 治疗合并症、非药物措施和疫苗接种是CKD患者的优先事项(作者结论)。
- 大流行期间及之后长期疾病管理均重要(作者结论)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is associated with increased risk of baseline mortality and severe COVID-19, but analyses across CKD stages, and comorbidities are lacking. In prevalent and incident CKD, we investigated comorbidities, baseline risk, COVID-19 incidence, and predicted versus observed one-year excess death. In a national dataset (NHS Digital Trusted Research Environment [NHSD TRE]) for England encompassing 56 million individuals), we conducted a retrospective cohort study (March 2020 to March 2021) for prevalence of comorbidities by incident and prevalent CKD, SARS-CoV-2 infection and mortality. Baseline mortality risk, incidence and outcome of infection by comorbidities, controlling for age, sex and vaccination were assessed. Observed versus predicted one-year mortality at varying population infection rates and pandemic-related relative risks using our published model in pre-pandemic CKD cohorts (NHSD TRE and Clinical Practice Research Datalink [CPRD]) were compared. Among individuals with CKD (prevalent:1,934,585, incident:144,969), comorbidities were common (73.5% and 71.2% with one or more condition[s] in respective data sets, and 13.2% and 11.2% with three or more conditions, in prevalent and incident CKD), and associated with SARS-CoV-2 infection, particularly dialysis/transplantation (odds ratio 2.08, 95% confidence interval 2.04-2.13) and heart failure (1.73, 1.71-1.76), but not cancer (1.01, 1.01-1.04). One-year all-cause mortality varied by age, sex, multi-morbidity and CKD stage. Compared with 34,265 observed excess deaths, in the NHSD-TRE and CPRD databases respectively, we predicted 28,746 and 24,546 deaths (infection rates 10% and relative risks 3.0), and 23,754 and 20,283 deaths (observed infection rates 6.7% and relative risks 3.7). Thus, in this largest, national-level study, individuals with CKD have a high burden of comorbidities and multi-morbidity, and high risk of pre-pandemic and pandemic mortality. Hence, treatment of comorbidities, non-pharmaceutical measures, and vaccination are priorities for people with CKD and management of long-term conditions is important during and beyond the pandemic.
引用
- Dashtban A, Mizani MA, Denaxas S, et al. A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. 2022. PMID: 35724769. doi:10.1016/j.kint.2022.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。